FLT3 and acute myeloid leukemia: In this setting (i.e., at relapse), AML is more oligoclonal, with leukemic clones harboring multiple adverse-risk genetic mutations, and appears to be more dependent on, or “addicted” to, FLT3 signaling, at least in vitro [48].